SEC Form 4 · accession 0001415889-18-000913
ACADIA PHARMACEUTICALS INC · ACAD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel B Soland
Director
Period of report
Jun 6, 2018
Accepted (ET)
Jun 8, 2018 · 5:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001070494
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $17.52 | Jun 6, 2018 | A | 15,000 | A | — | Jun 5, 2028 | Common Stock | 15,000 | 15,000 | D |
| Stock Option (right to buy)F2,F1 | $17.52 | Jun 6, 2018 | A | 15,000 | A | — | Jun 5, 2028 | Common Stock | 15,000 | 15,000 | D |
Explanation of responses
- F125% of the shares subject to the Stock Option vest and become exercisable at the end of each 3-month period following the date of grant.
- F2Annual committee grant.